Home » About Us

About Us

About touchINFECTIOUS DISEASES

Delivering online education is a skill and an art that we have perfected by experience, working with hundreds of renowned faculty members and many of the world’s leading medical societies.

touchINFECTIOUS DISEASES is proud to be at the forefront of on-demand and virtual formats, pushing the boundaries for online medical education.

  • Learn more from touchINFECTIOUS DISEASES with CME-accredited and independent learning activities
  • Watch highlights and coverage from leading international infectious disease congresses
  • Focused education on key topics in infectious diseases, developed in collaboration with pharma
  • Read the latest articles from our peer-reviewed therapy journals and unique expert insights developed for touchINFECTIOUS DISEASES

About Touch Medical Media Group Holdings Ltd

Touch Medical Media Group Holdings Ltd is a non-trading holding Company which includes the following wholly owned subsidiary companies within the group; Touch Medical Communications Ltd, Touch Independent Medical Education Ltd & Touch Medical Media Services Ltd

CME and Education is developed by Touch Independent Medical Education Ltd for touchINFECTIOUS DISEASES.

Learning Zone activities are developed by Touch Medical Communications Ltd for touchINFECTIOUS DISEASES and sponsored by the pharmaceutical industry.

Meet our experts
Laura Waters

University College London, UK

Laura Waters is a GU/HIV consultant and HIV & hepatitis lead at CNWL’s Mortimer Market Centre, London. She chair of BHIVA and on the BASHH Board, previous BHIVA conferences chair, previous chair of the BASHH HIV special interest group and involved is in several national guidelines. Laura is on the HIV Clinical Reference Group, advising NHS England about HIV care, co-chair of the HIV CRG drugs sub-group, a section lead for the HIV Commission and on the trials management group of the PrEP IMPACT trial. She has published and presented widely, is a regular columnist for Boyz magazine, and is a Terrence Higgins Trust trustee.

Louis Picker

Vaccine and Gene Therapy Institute, Oregon Health & Science University, FL, USA

Dr Louis J Picker is currently the Associate Director of the Vaccine and Gene Therapy Institute, a Senior Scientist in the Pathobiology and Immunology Division of the Oregon National Primate Research Center and a Professor in the Oregon Health & Science University’s Departments of Pathology and Molecular Microbiology and Immunology. Dr Picker was recruited to OHSU in 2000 from the Department of Pathology at the University of Texas Southwestern Medical Center at Dallas where he served as a Principal Investigator, Medical Director of the Flow Cytometry and Clinical Immunology Laboratory and Co-Director of the Division of Hematopathology and Immunology. He received his medical degree at the University of California, San Francisco in 1982, did an internship, residency and chief residency in Anatomic and Clinical Pathology at the Beth Israel Hospital and Harvard Medical School in Boston, Massachusetts from 1982-86 and received advanced training in Immunopathology and Experimental Pathology at Stanford University Medical Center in Palo Alto, California from 1986-89. Dr Picker is known for his work elucidating human/nonhuman primate (NHP) memory T cell biology, T cell mediated mechanisms of protection against persistent pathogens, the immunopathogenesis of AIDS and tuberculosis and HIV and TB vaccine development.

Giovanni Delogu

Catholic University of the Sacred Heart, Rome, Italy

Giovanni Delogu, PhD, is Associate Professor of Microbiology and Clinical Microbiology at the Catholic University of the Sacred Heart (Roma, Italy) – and Head of the Department of Laboratory Medicine at the Mater Olbia Hospital (Olbia, Italy). The main scientific interests involve research on tuberculosis (TB) and mycobacterial infections from different perspectives including: pathogenesis and host-pathogen interaction of TB using in vitro and in vivo models; development and evaluation of new antimicrobials and host-directed therapies against TB and other bacterial pathogens; microbiological and immunological diagnosis of TB; WGS and molecular epidemiology of TB; surveillance of antimicrobial resistance. Research in this field has been funded in the last ten years by the EU (FP6 & 7), Italian Minister of Health, Italian Minister of University and Scientific Research. The expertise gained in the TB field over 25 years have also been transferred to other fields of microbiology and infectious diseases, with a special focus on molecular microbiology, development and evaluation of new diagnostic systems.

  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72